group cognitive behavioral therapy for ibd patients

Conditions: Inflammatory Bowel Diseases

Summary: inflammatory bowel disease (ibd) patients commonly suffer from disturbed psychosocial functioning and poor quality of life compared to other chronic disease patients. clinicians are becoming growingly aware that addressing patients' psychological difficulties may improve disease management, however, there is not adequate evidence regarding the effect of psychotherapeutic interventions on psychosocial functioning and disease-related clinical and laboratory parameters. the aim of the present study is the evaluation of the effects of a targeted, cognitive behavioral psychotherapeutic intervention on symptom severity, levels of psychological distress and quality of life and inflammation and disease activity indices in ibd patients. an additional aim is the detection of psychological and biomedical parameters which may be associated with these effects.

background inflammatory bowel disease patients report increased levels of anxiety and depressive symptoms which are associated with poorer health-related quality of life (qol). in addition, they commonly experience disturbed self- and body-image thus being vulnerable to interpersonal difficulties and sexual dysfunction. there are several studies reporting that the presence of co-morbid depression is more strongly associated with increased financial cost and hospitalization rates, worse treatment compliance and major qol deficits compared to disease activity. for this reason, the current ecco-efcca patient guidelines strongly recommend regular psychiatric evaluation as a necessary part of patients' standard follow-up and put particular emphasis on treating anxiety and depressive symptoms with the use of appropriate pharmacological or psychosocial interventions. however, relevant literature is relatively sparse, lacking wide-scale randomized trials focusing on the efficacy of antidepressants and psychotherapy not only on alleviating patients' psychological distress but also on improving ibd clinical and laboratory severity indices. more specifically, a recent systematic review identified only one randomized clinical trial on the effect of antidepressants in ibd patients. in a similar vein, there is a limited number of randomized clinical trials focusing on the effect of brief psychotherapeutic interventions on patients' psychological burden, qol and disease progression. the importance of different immunoregulatory pathways mediated by several immunological cells subtypes and cytokines in the regulation of ibd has been demonstrated the last years. cytokines have been directly implicated in the pathogenesis of ibd in genetic and immunological studies, and they establish a crucial role in controlling intestinal inflammation and the associated clinical symptoms of ibd. despite the fundamental role of cytokines in controlling mucosal inflammation in ibd, to our knowledge, inflammation indices have never been evaluated as study end-points in investigations focusing on the role of psychotherapy on patients' qol. research hypotheses our primary research hypothesis is that brief psychotherapeutic intervention will reduce ibd patients' gastrointestinal symptoms and psychological distress and improve their sexual functioning and qol. a secondary hypothesis is that the observed improvement in psychosocial functioning will be accompanied by alterations in inflammation and disease activity indices. research aim in this context, the aim of the current prospective randomized controlled study will be the measurement of the effects of brief group cognitive behavioral psychotherapy on gastrointestinal symptom severity, psychological distress, sexual functioning, qol and inflammation and disease activity indices in ibd patients. an additional aim will be the detection of psychological and biomedical parameters which are associated with these effects.

Eligibility criteria:
inclusion criteria: * adult outpatients suffering from crohn's disease or ulcerative colitis according to the ecco-efcca patient guidelines, in both statuses "currently experiencing a flare/relapse" or "not currently experiencing a flare/relapse (in remission)" exclusion criteria: * major psychopathology * severe cognitive or neurological deficits * cancer * other severe chronic diseases or disabilities * lack of fluency in the greek language